CD20: B Cells' "Beacon" and the "Evergreen Target" of Immunotherapy

CD20: B Cells' "Beacon" and the "Evergreen Target" of Immunotherapy

In the vast realm of biology, proteins—as indispensable components of life activities—not only form the structural basis of cells but also deeply participate in various metabolic processes and signal transductions. Among them, CD20 protein has become a research hotspot due to its unique biological characteristics and pivotal role in the immune system.

I. Structure and Expression of CD20 Protein

CD20 (Cluster of Differentiation 20), also known as B-lymphocyte antigen CD20 or MS4A1, is a 33-37 kDa non-glycosylated phosphoprotein belonging to the transmembrane 4 superfamily A (MS4A) protein family. It consists of four hydrophobic transmembrane domains, one intracellular domain, and two extracellular loops, with both N- and C-termini located in the cytoplasm. Encoded by the MS4A1 gene, this gene is localized to the q12 region of human chromosome 11.

CD20 plays a critical role in B-cell development, starting expression from the pro-B cell stage in the bone marrow and persisting through the mature B-cell stage, but it is not expressed in plasma cells. Additionally, CD20 is highly expressed in various B-cell malignancies, such as B-cell lymphoma and chronic lymphocytic leukemia.

II. Biological Functions of CD20 Protein

B-Cell Activation and Differentiation: CD20 protein is a key factor in B-cell activation and differentiation. Upon antigen stimulation, CD20 interacts with the membrane-bound IgM (sIgM) of the B-cell receptor (BCR), triggering B-cell activation, proliferation, and differentiation to ultimately produce specific antibodies against foreign pathogens. Following B-cell activation, the BCR-CD20 complex dissociates, and phosphoproteins and calmodulin-binding proteins are temporarily recruited to CD20, participating in intracellular signal transduction.

Calcium Ion Flux Regulation: CD20 protein plays a significant role in regulating intracellular calcium ion concentrations. It is involved in the store-operated calcium entry (SOCE) process, enhancing intracellular calcium levels through calcium release-activated calcium (CRAC) channels—the primary mechanism for lymphocytes to elevate cytosolic calcium.

Cell Apoptosis Regulation: CD20 protein also participates in B-cell apoptosis, maintaining immune system homeostasis by regulating intracellular signaling pathways. In certain contexts, such as autoimmune diseases or tumorigenesis, CD20 helps modulate aberrant B-cell behavior by inducing apoptosis to preserve immune balance.

III. Clinical Applications of CD20 Protein

CD20 serves as a target for numerous monoclonal antibody drugs widely used in treating B-cell-related malignancies and autoimmune diseases. For example, rituximab (Rituximab), the world's first approved monoclonal antibody drug, is primarily used for non-Hodgkin's lymphoma and certain autoimmune conditions. Other anti-CD20 monoclonal antibodies include ofatumumab (Ofatumumab) and obinutuzumab (Obinutuzumab).

Divergent Mechanisms of Type I and Type II Anti-CD20 Monoclonal Antibodies:

Type I monoclonal antibodies engage complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC), inducing modulation in certain B-cell malignancies but not direct cell death. In contrast, Type II monoclonal antibodies mediate direct cell death via lysosomal pathways and participate in ADCC without promoting CDC or CD20 modulation.

IV. Research Progress and Challenges

Despite CD20's remarkable clinical success, many mysteries remain regarding its precise role in B-cell receptor signaling and the significant variability in its expression levels across disease states. Furthermore, CD20 downregulation in certain diseases may limit the efficacy of monoclonal antibody therapies.

Future research must further elucidate CD20's molecular mechanisms, develop more effective targeted therapies, and address drug resistance issues.

In conclusion, CD20 protein holds immense significance in B-cell biology and clinical therapy. With deeper insights into its mechanisms, CD20 promises to offer novel therapeutic strategies for a broader spectrum of diseases.

Recommended Products:

Data Sharing:

＞90% purity confirmed by SDS-PAGE & ＞85% purity by SEC-HPLC

References:

Silvia Delgado; Simon Faissner; Ralf A. Linker; Kottil Rammohan. Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment. Journal of Neurology, 2023.
Anand Kumar; Cyril Planchais; Rémi Fronzes; Hugo Mouquet; Nicolás Reyes. Binding mechanisms of therapeutic antibodies to human CD20. Science, 2020.
Stephen A. Beers; H T Claude Chan; Ruth R. French; Mark S. Cragg; Martin J. Glennie. CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies. Seminars in Hematology, 2010.
Gabriela Mladonická Pavlasová; Marek Mráz. The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy. Haematologica, 2020.